Breast cancer staging in a single session: Whole-body PET/CT mammography

Our objective was to compare the diagnostic accuracy of an all-in-one protocol of whole-body F-18-FDG PET/CT and integrated F-18-FDG PET/CT mammography with the diagnostic accuracy of a multimodality algorithm for initial breast cancer staging. Methods: Forty women (mean age, 58.3 y; range, 30.8-78.4 y; SD, 12 y) with suspected breast cancer were included. For the primary tumor, we compared F-18-FDG PET/CT mammography versus MRI mammography; for axillary lymph node status, F-18-FDG PET/CT versus clinical investigation and ultrasound; and for distant metastases, F-18-FDG PET/CT versus a multimodality staging algorithm. Histopathology and clinical follow-up served as the standard of reference. The Fisher exact test evaluated the significance of differences (P < 0.05). Alterations in patient management caused by F-18-FDG PET/CT were documented. Results: No significant differences were found in the detection rate of breast cancer lesions (F-18-FDG PET/CT, 95%; MRI, 100%; P = 1). F-18-FDG PET/CT correctly classified lesion focality significantly more often than did MRI (F-18-FDG PET/CT, 79%; MRI, 73%; P < 0.001). MRI correctly defined the T stage significantly more often than did F-18-FDG PET/CT (MRI, 77%; F-18-FDG PET/CT, 54%; P = 0.001). F-18-FDG PET/CT detected axillary lymph node metastases in 80% of cases; clinical investigation/ultrasound, in 70%. This difference was not statistically significant (P = 0.067). Distant metastases were detected with F-18-FDG PET/CT in 100% of cases, and the multimodality algorithm identified distant metastases in 70%. This difference was not statistically significant (P = 1). Three patients had extraaxillary lymph node metastases that were detected only by PET/CT (cervical, retroperitoneal, mediastinal/internal mammary group). F-18-FDG PET/CT changed patient management in 12.5% of cases. Conclusion: Our data suggest that a whole-body F-18-FDG PET/CT mammography protocol may be used for staging breast cancer in a single session. This initial assessment of the F-18-FDG PET/CT protocol indicates similar accuracy to MRI for the detection of breast cancer lesions. Although MRI seems to be more accurate when assessing the T stage of the tumor, F-18-FDG PET/CT seems able to more accurately define lesion focality. Although F-18-FDG PET/CT mammography was able to detect axillary lymph node metastases with a high sensitivity, this method cannot soon be ex-pected to replace the combination of clinical examination, ultrasound, and sentinel lymph node biopsy for axillary assessment.